论文部分内容阅读
目的：探讨肝动脉化疗栓塞与ＣＤ３ＡＫ细胞联合治疗中晚期肝癌的效果。方法：对３４例中晚期原发性肝癌采用经肝动脉化疗栓塞（ＴＡＣＥ）联合ＣＤ３ＡＫ细胞进行治疗（Ａ组）；同时对２７例相同患者单纯进行肝动脉化疗栓塞治疗（Ｂ组）。结果：①Ａ组部分缓解率为７６．５％（２６／３４），高于Ｂ组部分缓解率为５１．９％（１４／２７）（Ｐ＜０．０５）。②Ａ组中位生存期为２２．３月，Ｂ组为１５．７月，两组相比有显著差异（Ｐ＜０．０１）。１年、２年生存率Ａ组分别为７３．５％（２５／３４）和６０．０％（１８／３０）；均高于Ｂ组的４８．７％（１３／２７）和３２．０％（８／２５）（Ｐ＜０．０５）。③Ａ组ＣＤ３、ＣＤ４、ＣＤ４／ＣＤ８比值均有不同程度升高，ｓＩＬ－２Ｒ水平下降，而Ｂ组则相反。结论：ＴＡＣＥ与ＣＤ３ＡＫ细胞有协同治疗中晚期肝癌的作用，不但明显提高治疗效果，而且明显提高患者的免疫功能。
Objective: To investigate the effect of hepatic arterial chemoembolization combined with CD3AK cells in the treatment of advanced hepatocellular carcinoma. Methods: Thirty-four cases of advanced hepatocellular carcinoma were treated with transcatheter arterial chemoembolization (TACE) combined with CD3AK cells (group A); 27 cases of the same patients were treated with hepatic arterial chemoembolization (group B). Results: Partial remission rate in group 1A was 76.5% (26/34), higher than that in group B was 51.9% (14/27) (P<0.05). The median survival time was 22.3 months in group 2A and 15.7 months in group B. There was a significant difference between the two groups (P<0.01). The 1-year and 2-year survival rates in group A were 73.5% (25/34) and 60.0% (18/30), respectively; they were higher than those in group B (48.7%, 13/27, and 32.0). %(8/25)(P<0.05). In group 3A, the ratios of CD3, CD4, and CD4/CD8 increased to varying degrees, and the level of sIL-2R decreased, whereas in group B the opposite was observed. Conclusion: TACE and CD3AK cells have a synergistic effect on the treatment of advanced hepatocellular carcinoma, which not only improves the therapeutic effect, but also significantly improves the patient’s immune function.